Replimune Group (REPL) Peer Comparison
$18.84
$1.23
(6.98%)
As on 02-Nov-2026 13:39EST
Market cap
$1,669 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.2
Div. Yield
0 %
Edit
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,669 | 16,932 | 10,811 | 5,010 | 4,522 |
Revenue ($ Mln) |
-- | 2,497 | 102 | 1,156 | 497 |
Net Profit ($ Mln) |
-271.03 | 885.14 | -349.47 | -105.97 | 128.63 |
Net Margin (%) |
-- | 35.45 | -341.87 | -9.17 | 25.86 |
RoE (%) |
-146.13 | 46.96 | -22.16 | -- | 32.94 |
Price to Earnings |
-- | 20.78 | -- | -- | 42.02 |
Price-To-Book |
8.16 | 9.23 | 6.49 | 1,743.27 | 9.83 |
Income Statement ($ Mln)
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 2,320.13 | 39.20 | 1,730.66 | 379.81 |
|
Cost of Revenue
|
3.50 | 83.70 | -- | 71.76 | 123.24 |
|
Gross Profit
|
-3.50 | 2,236.43 | 39.20 | 1,658.90 | 256.57 |
|
Operating Expenses
|
319.92 | 1,364.24 | 388.60 | 802.39 | 281.64 |
|
Operating Profit (EBIT)
|
-319.92 | 872.19 | -349.40 | 856.51 | -25.07 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-314.49 | 941.21 | -311.62 | 696.62 | -21.08 |
|
Provision for Tax
|
-0.55 | 158.64 | -- | 13.98 | 0.27 |
|
Profit after Tax (Net Income)
|
-313.94 | 782.57 | -311.40 | 682.64 | -21.35 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
166.16 | 2,161.32 | 1,579.66 | -205.31 | 303.10 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
108.00 | 277.46 | 79.94 | 2,135.65 | 20.28 |
|
Current Liabilities
|
58.23 | 405.64 | 83.21 | 968.43 | 89.85 |
|
Total Liabilities
|
332.39 | 2,844.42 | 1,742.81 | 2,898.77 | 413.23 |
Assets ($ Mln)
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
53.27 | 1,401.13 | 871.60 | 624.82 | 156.10 |
|
Current Assets
|
279.12 | 1,443.29 | 871.21 | 2,273.95 | 257.13 |
|
Total Assets
|
332.39 | 2,844.42 | 1,742.81 | 2,898.77 | 413.23 |
|
Total Debt*
|
111.59 | 173.04 | 82.25 | 2,707.06 | 26.19 |
|
Net Current Assets
|
220.89 | 1,037.65 | 788.00 | 1,305.52 | 167.28 |
Cashflow ($ Mln)
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-280.34 | 884.27 | -232.89 | 711.20 | 42.03 |
|
Cash Flow from Investing Activities
|
310.84 | 350.44 | -521.06 | -861.98 | 2.16 |
|
Cash from Financing Activities
|
66.29 | -969.59 | 990.71 | 331.09 | -93.39 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-81.57 | 32.82 | -24.09 | 35.24 | -5.80 |
|
ROE (%)
|
-107.88 | 35.53 | -25.79 | -104.75 | -6.27 |
|
ROA (%)
|
-71.05 | 27.02 | -22.89 | 29.66 | -4.72 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | 33.73 | -794.39 | 39.44 | -5.62 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.07 | -0.17 | 1.15 | 0.14 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-26.95 | 50.13 | -39.11 | 287.90 | -140.64 |
|
EPS Growth (%)
|
-0.10 | 0.50 | -0.32 | 2.80 | -1.46 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-2.26 | 15.79 | -21.09 | 8.98 | -45.11 |
|
Price / Book Value
|
4.27 | 5.72 | 4.16 | -29.85 | 3.18 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-1.83 | 12.44 | -19.14 | 7.76 | -174.47 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.67 | 0.08 | 0.05 | -13.19 | 0.09 |
|
Short term debt to equity ratio
|
0.02 | -- | 0.01 | -2.85 | 0.02 |
|
Current Ratio
|
4.79 | 3.56 | 10.47 | 2.35 | 2.86 |
|
Quick Ratio
|
-- | 3.50 | -- | 2.27 | 2.56 |
|
Interest Coverage
|
-34.50 | -- | -1,250.50 | 5.58 | -- |
Operating Efficiency Ratios
| Replimune Group (REPL) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Caredx Inc (CDNA) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 12.37 | -- | 10.49 | 11.22 |
|
Asset Turnover
|
0.00 | 0.80 | 0.03 | 0.75 | 0.84 |
|
Receivable days
|
-- | 43.48 | 8.82 | 35.90 | 51.56 |
|
Inventory Days
|
-- | 96.17 | -- | 261.74 | 68.47 |
|
Payable days
|
784.37 | 147.97 | -- | 159.73 | 26.19 |
|
Cash Conversion Cycle
|
-- | -8.32 | -- | 137.90 | 93.85 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
